{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:21:20Z","timestamp":1780352480356,"version":"3.54.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["04-2023-0690"],"award-info":[{"award-number":["04-2023-0690"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2021-NR060140"],"award-info":[{"award-number":["RS-2021-NR060140"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) and constitutes approximately 15\u201320% of all BC cases. This subtype has the most aggressive behavior and the worst prognosis. Numerous studies have been conducted over the past several decades to address the lack of clinically available treatment options. In particular, potential markers targeting effective treatment options have been actively studied. However, these efforts were hindered by the complex mechanisms of TNBC, and no study has demonstrated a model with a predictive performance exceeding 0.85. This study developed TNBC prognosis predictive models with a predictive performance exceeding 0.94. Applying the nine selected markers to five independent datasets demonstrated their potential as TNBC-specific prognostic markers. Most of these genes (including\n                    <jats:italic>GPR61<\/jats:italic>\n                    ,\n                    <jats:italic>PZP<\/jats:italic>\n                    ,\n                    <jats:italic>IGFL1<\/jats:italic>\n                    , and\n                    <jats:italic>AHCTF1<\/jats:italic>\n                    ) are associated with overall survival (OS) in patients with TNBC. Based on these results, these nine selected genes may serve as prognostic markers for OS in patients with TNBC.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0348414","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:31:16Z","timestamp":1777915876000},"page":"e0348414","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9294-1518","authenticated-orcid":true,"given":"Suhyun","family":"Hwangbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoojin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yong","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"2","key":"pone.0348414.ref001","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/0008-5472.CAN-21-0621","article-title":"Network analysis identifies regulators of basal-like breast cancer reprogramming and endocrine therapy vulnerability","volume":"82","author":"SR Choi","year":"2022","journal-title":"Cancer Res"},{"issue":"4","key":"pone.0348414.ref002","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/jcm12041524","article-title":"Current treatment landscape for early triple-negative breast cancer (TNBC)","volume":"12","author":"J Lee","year":"2023","journal-title":"J Clin Med"},{"issue":"2","key":"pone.0348414.ref003","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00109.2021","article-title":"Heterogeneity within molecular subtypes of breast cancer","volume":"321","author":"KM Turner","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"pone.0348414.ref004","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41597-023-02253-5","article-title":"Global trends and forecasts of breast cancer incidence and deaths","volume":"10","author":"Y Xu","year":"2023","journal-title":"Sci Data"},{"issue":"11","key":"pone.0348414.ref005","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1074\/mcp.M115.048967","article-title":"Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a protein signature in tissue samples","volume":"14","author":"M Campone","year":"2015","journal-title":"Mol Cell Proteomics"},{"issue":"16","key":"pone.0348414.ref006","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"A Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0348414.ref007","doi-asserted-by":"crossref","first-page":"212540","DOI":"10.7573\/dic.212540","article-title":"Advances in the use of PARP inhibitor therapy for breast cancer","volume":"7","author":"KE McCann","year":"2018","journal-title":"Drugs Context"},{"key":"pone.0348414.ref008","doi-asserted-by":"crossref","first-page":"287","DOI":"10.18632\/oncoscience.474","article-title":"Translating the role of PARP inhibitors in triple-negative breast cancer","volume":"6","author":"M Beniey","year":"2019","journal-title":"Oncoscience"},{"key":"pone.0348414.ref009","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4137\/CIN.S9983","article-title":"TNBCtype: A subtyping tool for triple-negative breast cancer","volume":"11","author":"X Chen","year":"2012","journal-title":"Cancer Inform"},{"issue":"17","key":"pone.0348414.ref010","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1002\/cam4.3284","article-title":"Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy","volume":"9","author":"Y Zhao","year":"2020","journal-title":"Cancer Med"},{"key":"pone.0348414.ref011","article-title":"Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer","author":"DG Stover","year":"2015","journal-title":"Breast"},{"issue":"2","key":"pone.0348414.ref012","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: promising prognostic biomarkers currently in development","volume":"21","author":"J Sukumar","year":"2021","journal-title":"Expert review of anticancer therapy"},{"issue":"6","key":"pone.0348414.ref013","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3390\/cancers12061404","article-title":"Neoadjuvant treatment for triple negative breast cancer: Recent progresses and challenges","volume":"12","author":"JS Lee","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0348414.ref014","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10549-011-1554-7","article-title":"Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"132","author":"M Ono","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"pone.0348414.ref015","doi-asserted-by":"crossref","first-page":"936","DOI":"10.7150\/jca.52439","article-title":"Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer","volume":"12","author":"Y Han","year":"2021","journal-title":"J Cancer"},{"issue":"12","key":"pone.0348414.ref016","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.2174\/1389450115666141106151143","article-title":"Triple negative breast cancer - BCL2 in prognosis and prediction. Review","volume":"15","author":"K Bouchalova","year":"2014","journal-title":"Curr Drug Targets"},{"issue":"11","key":"pone.0348414.ref017","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1093\/annonc\/mdt277","article-title":"Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings","volume":"24","author":"TMA Abdel-Fatah","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"pone.0348414.ref018","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s43856-023-00311-y","article-title":"Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer","volume":"3","author":"M Ensenyat-Mendez","year":"2023","journal-title":"Commun Med (Lond)"},{"issue":"19","key":"pone.0348414.ref019","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1158\/1078-0432.CCR-19-3255","article-title":"Current panorama and challenges for neoadjuvant cancer immunotherapy","volume":"26","author":"JC Benitez","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"pone.0348414.ref020","first-page":"1609","article-title":"A perspective on anti-EGFR therapies targeting triple-negative breast cancer","volume":"6","author":"K Nakai","year":"2016","journal-title":"Am J Cancer Res"},{"key":"pone.0348414.ref021","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.2147\/OTT.S223603","article-title":"Supervised machine learning predictive analytics for triple-negative breast cancer death outcomes","volume":"12","author":"Y Xu","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"1","key":"pone.0348414.ref022","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s12885-019-5703-4","article-title":"Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer","volume":"19","author":"Y Yang","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"pone.0348414.ref023","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3390\/cancers15020402","article-title":"Schlafen 12 Slows TNBC tumor growth, induces luminal markers, and predicts favorable survival","volume":"15","author":"SK Singhal","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0348414.ref024","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2307\/2532740","article-title":"Maximally selected rank statistics","volume":"48","author":"B Lausen","year":"1992","journal-title":"Biometrics"},{"issue":"3","key":"pone.0348414.ref025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-020-06030-5","article-title":"A clinical calculator to predict disease outcomes in women with triple-negative breast cancer","volume":"185","author":"M-YC Polley","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"pone.0348414.ref026","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1073\/pnas.1320239111","article-title":"G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion","volume":"111","author":"ME Feigin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0348414.ref027","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12877-022-02936-5","article-title":"The impact of chemotherapy and survival prediction by machine learning in early Elderly Triple Negative Breast Cancer (eTNBC): A population based study from the SEER database","volume":"22","author":"K Huang","year":"2022","journal-title":"BMC Geriatr"},{"issue":"4","key":"pone.0348414.ref028","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4143\/crt.2024.100","article-title":"A 10-Gene signature to predict the prognosis of early-stage triple-negative breast cancer","volume":"56","author":"CM Kim","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"1","key":"pone.0348414.ref029","doi-asserted-by":"crossref","first-page":"30855","DOI":"10.1038\/s41598-024-81503-x","article-title":"Prognostic model based on tumor stemness genes for triple-negative breast cancer","volume":"14","author":"M Ouyang","year":"2024","journal-title":"Sci Rep"},{"issue":"10","key":"pone.0348414.ref030","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1007\/s12325-023-02577-z","article-title":"An EMT-Related gene signature to predict the prognosis of triple-negative breast cancer","volume":"40","author":"B Zhang","year":"2023","journal-title":"Adv Ther"},{"issue":"10","key":"pone.0348414.ref031","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/cancers16101791","article-title":"Overall Survival and prognostic factors in metastatic triple-negative breast cancer: A national cancer database analysis","volume":"16","author":"M Kesireddy","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0348414.ref032","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4143\/crt.2024.937","article-title":"Machine learning-based prognostic gene signature for early triple-negative breast cancer","volume":"57","author":"JW Kim","year":"2025","journal-title":"Cancer Res Treat"},{"issue":"1","key":"pone.0348414.ref033","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12672-025-04251-y","article-title":"Triple-negative breast cancer survival outcomes: Prognostic model validated with SEER database","volume":"17","author":"H Gao","year":"2026","journal-title":"Discov Oncol"},{"issue":"1","key":"pone.0348414.ref034","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41698-024-00559-0","article-title":"Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1\/2 mutations","volume":"8","author":"WK Park","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"pone.0348414.ref035","article-title":"Impact of pathologic complete response on the prognosis of triple-negative breast cancer patients: A cohort study","volume":"15","author":"RE Assun\u00e7\u00e3o Ribeiro da Costa","year":"2023","journal-title":"Cureus"},{"key":"pone.0348414.ref036","doi-asserted-by":"crossref","first-page":"105607","DOI":"10.1016\/j.ijmedinf.2024.105607","article-title":"Survival analysis for lung cancer patients: A comparison of Cox regression and machine learning models","volume":"191","author":"S Germer","year":"2024","journal-title":"Int J Med Inform"},{"key":"pone.0348414.ref037","doi-asserted-by":"crossref","first-page":"1049787","DOI":"10.3389\/fonc.2023.1049787","article-title":"A comparison of machine learning models and Cox proportional hazards models regarding their ability to predict the risk of gastrointestinal cancer based on metabolic syndrome and its components","volume":"13","author":"TT Tran","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0348414.ref038","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-024-00665-z","article-title":"EMBER creates a unified space for independent breast cancer transcriptomic datasets enabling precision oncology","volume":"10","author":"C Ronchi","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"pone.0348414.ref039","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-020-05958-y","article-title":"Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-\u03b2\/SMAD signaling","volume":"185","author":"R Kumar","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0348414.ref040","doi-asserted-by":"crossref","first-page":"985861","DOI":"10.3389\/fimmu.2022.985861","article-title":"Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer","volume":"13","author":"K Fang","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"pone.0348414.ref041","first-page":"2598","article-title":"An immunogenic cell death-related classification predicts response to immunotherapy and prognosis in triple-negative breast cancer","volume":"15","author":"X-Y Cheng","year":"2023","journal-title":"Am J Transl Res"},{"key":"pone.0348414.ref042","doi-asserted-by":"crossref","unstructured":"Conte B, Bras\u00f3-Maristany F, Hern\u00e1ndez AR, Pascual T, Villacampa G, Schettini F, et al. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies. EBioMedicine. 2024;102.","DOI":"10.1016\/j.ebiom.2024.105043"},{"key":"pone.0348414.ref043","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2147\/IJGM.S457329","article-title":"Nomograms Predict PFS and OS for SCLC patients after standardized treatment: A real-world study","volume":"17","author":"K Li","year":"2024","journal-title":"Int J Gen Med"},{"issue":"3","key":"pone.0348414.ref044","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4143\/crt.2018.508","article-title":"Development of web-based nomograms to predict treatment response and prognosis of epithelial ovarian cancer","volume":"51","author":"SI Kim","year":"2019","journal-title":"Cancer Res Treat"},{"key":"pone.0348414.ref045","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.35261","article-title":"Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding","volume":"130","author":"X Hou","year":"2024","journal-title":"Cancer"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0348414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:31:24Z","timestamp":1777915884000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0348414"}},"subtitle":[],"editor":[{"given":"Julie","family":"Decock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0348414","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}